BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 27, 2024
See today's BioWorld
Home
» Santhera sinks on negative CHMP vote for Raxone in DMD; firm plans appeal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Santhera sinks on negative CHMP vote for Raxone in DMD; firm plans appeal
Sep. 18, 2017
By
Nuala Moran
No Comments
LONDON – Shares in Santhera Pharmaceutical AG crashed by 58 percent on Friday morning after the EMA gave a thumbs down to Raxone (idebenone) as a treatment for the respiratory complications of Duchenne muscular dystrophy (DMD).
BioWorld